Israeli pharmaceutical company Can-Fite BioPharma Ltd. has announced that it has raised NIS 26.5 million ($7.2 million) in its secondary offering on the Tel Aviv stock exchange. The company says that it will direct the funds towards a phase II/III clinical trial of its psoriasis treatment.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments